About Us
Pioneering the future of multi-cancer early detection through innovative liquid biopsy technology.
Yenos Analytical
Our mission is to develop reliable early cancer and disease screening tests that provide actionable insights when traditional methods yield inconclusive results.
Through our advanced microRNA-based diagnostic platform, we're revolutionizing liquid biopsy technology to enable accurate, non-invasive early detection of multiple cancer types from a simple urine sample.
We are committed to making early cancer detection accessible, convenient, and reliable, ultimately saving lives through timely intervention and treatment.
Our Story
The name “Yenos” derives from the Greek word which means birthing, family, and origin—reflecting our fundamental commitment to the origins of life and health. Just as the Danish botanist Wilhelm Johannsen coined the word "gene" in 1909 to describe the Mendelian units of heredity, we honor this scientific heritage by focusing on the molecular foundations of disease.
Founded on the principle that early detection is the cornerstone of effective cancer treatment, Yenos Analytical was established to address critical gaps in current screening methodologies. Traditional cancer screening tests often produce false positives or false negatives, leaving patients and healthcare providers uncertain about next steps.
Our company was born from a vision to transform cancer diagnostics by leveraging breakthrough discoveries in molecular biology—specifically, the role of microRNA in cellular function and disease progression. We recognized that by developing a highly accurate, patient-friendly testing platform, we could fundamentally change how cancer is detected and managed.
Today, Yenos Analytical stands at the forefront of liquid biopsy innovation, urging health insurers to include our tests in routine adult check-ups and making early cancer detection a standard part of preventive healthcare.
Scientific Leadership
Yenos Analytical is led by a distinguished retired Professor from the University of California at Santa Cruz, whose extensive career spans NASA research initiatives, NIH grantee projects, and pharmaceutical biotechnology innovation. She is an active member of the American Association for Cancer Research (AACR).
With decades of experience in assay development and molecular diagnostics, our founder has pioneered breakthrough methodologies in microRNA quantification. This expertise forms the foundation of our patented analytical platform for accurate detection of cancer biomarkers in liquid biopsies.
Under this visionary leadership, our team combines rigorous scientific methodology with a deep commitment to improving patient outcomes through accessible, reliable diagnostic solutions.
Our microRNA-Based Diagnostic Platform
Leveraging Nobel Prize-winning discoveries to revolutionize cancer detection
Exceptional Accuracy
Our patented technology enables precise quantification of microRNA biomarkers, providing highly accurate early detection of multiple cancer types with minimal false positives.
Non-Invasive Collection
Unlike traditional biopsies, our test requires only a simple urine sample, making cancer screening accessible, comfortable, and convenient for patients.
Scientific Foundation
Built on breakthrough microRNA research recognized by the 2024 Nobel Prize in Physiology or Medicine, our technology represents the cutting edge of molecular diagnostics.
Advanced Innovation
Our nanopore-based analytical approach allows for unprecedented sensitivity in detecting early-stage cancers, enabling intervention when treatment is most effective.